Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03644966 · ClinicalTrials.gov registry record · NA

Probiotics and Multi-Drug Resistant Urinary Tract Infection

A NA study of Urinary Tract Infections and Antibiotic Resistant Infection, sponsored by Ochsner Health System.

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT03644966 is a NA study of Urinary Tract Infections and Antibiotic Resistant Infection that has completed, run by Ochsner Health System. The registered enrollment target is 25 participants, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03644966, a NA study of Urinary Tract Infections and Antibiotic Resistant Infection, has completed, sponsored by Ochsner Health System.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs.

Interventions

  • OTHER Placebo
  • DRUG Antibiotics
  • DIETARY_SUPPLEMENT Bifidobacterium infantis

Study Locations (1)

Louisiana

  • Ochsner Health System - Jefferson

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2018-07-05
Est. Completion 2022-12-15
Phase NA

Sponsor

Ochsner Health System

29 total trials

What the Registry Record Tells You About NCT03644966

The ClinicalTrials.gov registry entry for NCT03644966 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 458-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target (95% lower). The listed sponsor is Ochsner Health System, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Urinary Tract Infections appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03644966 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.

Frequently Asked Questions

What is clinical trial NCT03644966 about?

NCT03644966 is a clinical study titled "Probiotics and Multi-Drug Resistant Urinary Tract Infection". This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs.

What is the current status of trial NCT03644966?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2018-07-05. Estimated completion is 2022-12-15.

What conditions does trial NCT03644966 study?

This clinical trial studies the following conditions: Urinary Tract Infections, Antibiotic Resistant Infection, Recurrent Uti.

What interventions are being tested in trial NCT03644966?

The interventions under investigation include: Placebo (OTHER), Antibiotics (DRUG), Bifidobacterium infantis (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03644966?

This trial is sponsored by Ochsner Health System, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03644966 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Tract Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.